1841 long term management and outcomes of recurrences following radio frequency ablation of renal tumors

You have accessJournal of UrologyKidney Cancer: Advanced (I)1 Apr 20131841 LONG TERM MANAGEMENT AND OUTCOMES OF RECURRENCES FOLLOWING RADIO FREQUENCY ABLATION OF RENAL TUMORS Gideon Lorber, Arturo Castro, Mehul Doshi, Vladislav Gorbatiy, and Reymond Leveillee Gideon LorberGideon Lorber Miami, FL More articles by this author , Arturo CastroArturo Castro Miami, FL More articles by this author , Mehul DoshiMehul Doshi Miami, FL More articles by this author , Vladislav GorbatiyVladislav Gorbatiy Miami, FL More articles by this author , and Reymond LeveilleeReymond Leveillee Miami, FL More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2013.02.2224AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES We present the long term management and oncological outcomes of patients diagnosed with recurrent renal tumors following primary radiofrequency ablation (RFA) of renal cell carcinoma (RCC). METHODS We reviewed our prospectively collected database of patients with renal masses treated between November 2001 and October 2012 with laparoscopic (LRFA) or computed tomography (CT) guided percutaneous RFA (CTRFA). All treatments were performed with real-time temperature monitoring to ensure target ablation temperature was adequately obtained. Inclusion criteria consisted of patients with a follow-up (FU) longer than 48 months who developed a recurrence following RFA of a biopsy confirmed RCC. FU consisted of physical examination, serum creatinine and contrast enhanced radiographic imaging (CT or MRI). Recurrence was defined as enhancement of >20 Hounsfield units post contrast confirmed as RCC by biopsy or documented to exhibit persistent growth on serial imaging. We reviewed the management approaches of these patients as well as complication rate and overall survival. RESULTS Out of 434 RFA cases, a total of 77 treatments in 67 patients had a FU longer than 48 months. In this group 6 cases, in 5 patients, met the inclusion criteria of recurrent RCC following primary treatment for RCC. Five were biopsy confirmed recurrent RCC tumor. The mean disease free interval was 27 months (5 to 42 months), the mean FU was 71 months (54 to 96 months) and the mean renal mass size was 2.8 cm (1 to 4 cm). The management of the recurrences consisted of repeat CTRFA in 3 cases, repeat LRFA in 2 cases and nephrectomy in 1 case. Complication rate was 17% (1 out of 6) which consisted of Clavien grade 1 complication. One patient died in the course of the study bringing our survival rate to 83%. CONCLUSIONS The low recurrence rate of 8% and adequate secondary treatment with no significant morbidities point to the oncologic efficacy and safety of RFA. © 2013 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 189Issue 4SApril 2013Page: e756 Peer Review Report Advertisement Copyright & Permissions© 2013 by American Urological Association Education and Research, Inc.MetricsAuthor Information Gideon Lorber Miami, FL More articles by this author Arturo Castro Miami, FL More articles by this author Mehul Doshi Miami, FL More articles by this author Vladislav Gorbatiy Miami, FL More articles by this author Reymond Leveillee Miami, FL More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...